If there is positive news from their discussion with FDA on trial with clear design approved, this one will soar to above $3 in a blink of the eye! Believe me, it will come soon enough. At this bargain price, pick up as many as you can. CRMD will be the best performing stock by the end of the year.
While longs might suffer as practically all biotech investors are during the sell-off, at least the co timed the secondary well enough to reap in another 100 million. I think such strong finance will pay off in the negotiation with large pharmas for partner. This is a solid co and will do well. Patience is needed though. Look like you have shorted the stock and hope to cover at $14.
This is the worst time to have bad news for any biotech. People are already jumpy with all the talk of "overvalue" in the sector and even big profitable ones such as GILD, BIIB and CELG cut down seriously. I am afraid HALO will go down a lot more under such circumstances. This tells you Kirk's connection is no guarantee for success. If you believe in him, you might as well put your money in his XON. He has just bought 600,000 more shares of the co.recently.
If the top line data for MS trial is positive, it will trade above $4. If negative, it will go to under $2 which should be a good price to buy based on the pipeline of numerous drugs to be developed. Being a channel collaborator for XON, the share price should be relatively protected and buying big time should be a no brainer. For longs, we may not relish that opportunity as that means the MS trial is not successful. We'll know in less than a month. GLTA.
Well, this is an even better price now", yet I bet you will now be hesitant to buy. Such is human nature. One has to overcome that to make REAL money. When there is blood and tremendous fear on the street, it is the time to buy. When everybody thinks sky is the limit, it is the time to sell. Very few can be so disciplined, so majority of investors lose money.
I am not sure about this so-called Eberwein effect". I bought in another co, DRAD, with this guy's investment in the co, then observed equally disappointing stock performance as OTIV. I am holding two large positions with substantial loss in both. May be it is the kiss of death when the E guy is involved. Anyone knows of any stock this guy is involved and is doing well? The only saving grace for DRAD is at least it pays a 5% dividend to ease the pain of holding it. There is nothing for OTIV shareholders. When management declined to make forward guidance, it is a bad sign. Master Card has just linked up its digital payment with a co and also invested in it, while AAPL is rumored to get mobile payment going soon. Where is OTIV's place in all these development?
I saw the several pages of analysis with a detailed discussion on IV site. This one is going to break out with such high short position. I believe it will hit the target price in six months. My opinion only.
It is going to break 5 today and stay there at the close of the market.
Waiting for news on its discussion with FDA on trial design and requirements as well as its plan on label expansion in EU. Any of the above will push its share over $3. Should be within one to two months for news.
Don't count on any decision made by FDA. Every single decision FDA has made was against AMRN. Law suit or making it public how FDA had done to AMRN is the only way to get any potential justice. This is an agency out of control making arbitrary decisions against small biotech cos on behalf of large pharmas with reasons we can only speculate.
It is silly to believe earnings will have impact on developmental biotechs. Nobody expects earnings at this stage, but the expected drug advancement will be. It is important to hear the management in the cc. I believe management will be upbeat and outline the progress as well as what we can expect from all the clinical activities. Finances should be solid from the recent secondary share offering with the current S/P well above the offering price. All good signs.
Sentiment: Strong Buy
I am not sure why your post received two thumb down! You spoke the truth as there were so many failures in attempts for cancer cure, particularly for small biotechs. The way for such investment is to use the "shot gun" approach which is to buy a basket of co and diversify your intended fund in many cos to offset losses. It is similar to many hedge funds that short biotechs and they short a bunch knowing only one out of 10 at best may succeed in its drug development. That's why they always make money at the end.
Good analysis of the situation. Many sellers were in this stock due to the SA article and are really short term players. The fact share never went down to even under $11 speaks to the strength of the stock and the high demand for it. Since I knew we wouldn't never be able to get it at the offering price, I added to my position today. In three months, this will be a non event with so many positive news in store for us. Barring international events, Monday should be a good day for the stock, now that most the short term players are out of the stock.
cgg, you got it right. If you recall, management did mention they intended to have at least one partnership deal for this year. With cash in hand, they will be in a lot better and stronger position to make a better deal. If the raise of money helps to get a better deal, I am all for it as the deal will propel our share price beyond the current level big time.
Yes, it is clear that some big boys want to be in and asked the co to issue shares. I see this happened all the time with cos that have promising products. They recognize the value of the pipeline of this co, so decide to take positions. This actually bodes ery well for the future. These big boys have access to information we don't have. In a way, these actions can be part of our DD for the co. Despite its 8% drop due to this news today, I feel positive overall. Let's face it, we don't invest in this co for a mere 10% gain. If it will ultimate produce positive trial result and propel the price to over 100%, who cares for the 8% drop at this point.
You are absolutely correct in that small investors are almost never able to get the shares at the offering price. These shares have already been spoken for. In my most recent experiences, I have three biotechs with secondary offering and here are the result: SYN offered at $1 and now is at $2.75 or so, ZIOP at $3 and now $4.65, then SGMO at $9 and now at $19. These changes in prices occurred between one to three months' time. So often small biotechs offer secondary shares to meet the demand/request of large players. Unless the co is in distress without good prospect (INO definitely is not), it share price will inevitably go up after the initial drag of the announcement. I think INO is in a sweet spot with institutions wanting in! Give it a couple months at most, it will be at high 4s.
There will be more to go down. Think about it. While we have been waiting for good news concerning trials which propelled pricerecently higher. Why wouldn't the co wait for the result before raising money, if the trial is successful as we all are expecting? I am now beginning to wonder the timing of the raise. Will wait until the news. Stock has been a stellar performer based on the expected trial success and this early secondary offering seems to raise doubts of the success. Been burned by similar biotech investments, so I am very cautious and analyze the co moves carefully.
I suggest to wait as the secondary offering will be priced at $3, so wait until the pricing is announced. Then go ahead and buy. Why buy now when you can buy at lower price? I am very long and will add to my already large position when it comes down to $3 or lower.
The trade down was ridiculous. This is a co now profitable for two quarters already and pays a 5% dividend. Management sounded that they are committed to this level of dividend. I like the way they said "shareholders' values" many times in the cc. I don't mind waiting for better share price while getting paid 5% a year. Beats money in the bank!
If one is so concerned with funds that include MACK in their portfolio, one doesn't need to go any further than looking into Fidelity which owns 15% of the outstanding shares. As for me, I believe the heavy insiders' buying is a lot more meaningful as an indicator. They bought a very large number of shares with their own money in the open market, despite options they have all received. Funds buy or sell shares using others' money. These insiders bought recently with their own hard earned money. To me. that is sufficient evidence to show their confidence in the co and its progress. I like that in companies I invest in.